[SYK] Stryker: Q3 2026 earnings preview, cyberattack backlog vs. vascular supply

Stryker is one of the world's largest medical technology companies, selling surgical power tools, endoscopy systems, hospital beds and emergency equipment, stroke and peripheral vascular thrombectomy devices, knee, hip and trauma implants, and the Mako orthopaedic surgical robot to hospitals, ambulatory surgery centers and physicians[1]. For this Stryker Q3 2026 earnings preview, the Drillr earnings calendar lists a call on 2026-10-29 covering the third quarter of 2026, ending September 30, 2026; the company had not separately announced that date[2]. In the latest reported quarter, the second quarter of 2026, Stryker's net sales rose 9.4% to $6.589 billion, organic sales grew 9.0%, the adjusted operating margin widened 170 basis points to 27.4%, and adjusted earnings per share rose 17.9% to $3.69[3][4]. On July 30 the company narrowed its full-year 2026 guidance to organic sales growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10[5], and management said on the call that hitting the midpoint requires roughly 11% organic growth in the second half[6]. As of October 1, 2026, the average of 16 analysts compiled by Drillr put third-quarter revenue at $6.646 billion (range $6.516 billion to $6.736 billion), about 9.7% above the $6.057 billion reported in the third quarter of 2025, and adjusted EPS at $3.56 (range $3.43 to $3.72)[7][8]; against the $3.19 prior-year adjusted EPS recorded in the Drillr earnings calendar, that estimate implies growth of about 11.6%[2].

Three things matter most in this report. First, whether organic growth approaches the roughly 11% the second half requires: the March cyberattack held first-quarter organic growth to 2.4%[9] before it recovered to 9.0% in the second quarter[3], and the third quarter is the first full quarter after production recovered, so it will show whether the backlog of beds, surgical equipment and Mako orders is turning into sales at the pace management described. Second, whether U.S. vascular sales stop falling: a supply disruption at the Inari peripheral vascular plant cut second-quarter U.S. Vascular sales 6.7% year over year[10], the company said in July that the back-order position would reach a manageable level by the end of the third quarter[11], and the report will show whether the outage caused a temporary shortage or a lasting loss of customers. Third, whether the adjusted margin keeps expanding while remediation costs persist: lower tariffs helped the second-quarter margin, but idle-capacity and IT remediation costs from the cyberattack will continue into the second half[6][12], so third-quarter margins will decide how credible the full-year EPS guidance is.

Company Background and Business Structure

Stryker is a device maker that sells mainly through its own direct sales force into operating rooms and hospitals, and the U.S. market supplies most of its revenue. Orthopaedic surgeon Dr. Homer H. Stryker founded the business in 1941, the company was incorporated in Michigan in 1946, and its products are sold in about 61 countries through company-owned subsidiaries, branches and third-party dealers, with most products marketed directly to doctors, hospitals and other healthcare facilities[1]. At the end of 2025 the company had about 56,000 employees, roughly 28,000 of them in the United States[13]; that year U.S. sales of $19.006 billion made up about 76% of total sales of $25.116 billion[14].

The company reports two segments, MedSurg and Neurotechnology and Orthopaedics, and the first is both larger and faster growing. In 2025 MedSurg and Neurotechnology sales were $15.647 billion, or 62% of the total, and Orthopaedics sales were $9.469 billion, or 38%[1]. Within MedSurg and Neurotechnology, Medical (beds, stretchers, emergency equipment and clinical communication platforms) sold $4.204 billion, Endoscopy (endoscopes and operating-room imaging and communications) $3.807 billion, Instruments (surgical power tools, navigation and safety equipment) $3.183 billion, Neuro Cranial (open-skull surgery and biomaterials) $2.485 billion, and Vascular (stroke and peripheral thrombectomy) $1.968 billion[15]. Within Orthopaedics, Trauma and Extremities sold $3.948 billion, Knees $2.656 billion and Hips $1.865 billion, while Spinal Implants fell to $185 million after the U.S. spine business was sold in 2025[16]; in the first quarter of 2026 the company combined Mako robotics, orthopaedic power tools and cutting accessories into a new Ortho Tech business and recast its historical segment data on that basis[9][17].

Acquisitions are Stryker's first capital-allocation priority, and its two most recent deals both landed in peripheral vascular. In February 2025 the company bought thrombectomy device maker Inari for $80 per share, or $4.810 billion net of cash acquired, and placed it in the Peripheral Vascular business within MedSurg and Neurotechnology[18]; in May 2026 it acquired AVS, which is developing an intravascular lithotripsy platform, for $435 million in net cash plus up to $400 million in milestone payments[19]. Operationally, substantially all manufactured products are stocked in inventory while some MedSurg products are assembled to order, capital equipment sales are generally highest in the fourth quarter, orthopaedic implant surgeries are typically lower in summer, and some raw materials come from single suppliers[20].

Financial History and Current Position

Stryker's 2025 growth came mainly from procedure and shipment volume rather than pricing. Net sales reached $25.116 billion in 2025, up 11.2% as reported, and organic growth excluding acquisitions, divestitures and currency was 10.3%[21], with unit volume contributing 9.9 percentage points and price only 0.4 point[22]. By segment, MedSurg and Neurotechnology grew 15.7% including the Inari consolidation, while Orthopaedics grew only 4.3% as reported because of the divested U.S. spinal implants business; excluding acquisitions and divestitures, Orthopaedics grew 9.6% organically[14][22].

Reported and adjusted profit diverged sharply in 2025, mainly because of acquisition amortization, impairments and tax items. The 2025 gross margin was 64.0%[23], reported operating income was $4.889 billion, or about 19.5% of sales, and adjusted operating income, which excludes acquisition and integration costs, intangible amortization, restructuring, impairments and recall items, was $6.603 billion, a 26.3% adjusted operating margin[24]. Reported EPS was $8.40 and adjusted EPS was $13.63, up 11.8%[21].

Operating cash flow in 2025 was largely consumed by acquisitions and dividends, so debt rose. Operating cash flow was $5.044 billion, capital expenditure $761 million, acquisition spending $4.960 billion and dividends $1.284 billion, and total debt ended the year at $15.859 billion[25], against cash, cash equivalents and marketable securities of $4.100 billion[26]. Contractually, $1.000 billion of debt was due in 2026 and a further $3.988 billion falls due in 2027-2028[27].

The cyberattack split Stryker's first-half 2026 income statement into two very different quarters. On March 11 the company identified a cybersecurity incident that caused a global disruption to its Microsoft environment[28], the next day it said order processing, manufacturing and shipping were still disrupted[29], and in April it concluded that the incident had a material impact on first-quarter results[30]. First-quarter sales were $6.020 billion with organic growth of 2.4%, the adjusted operating margin contracted 180 basis points to 21.1%, and adjusted EPS fell 8.5% to $2.60[9]; second-quarter sales recovered to $6.589 billion with 9.0% organic growth, a 27.4% adjusted operating margin, reported EPS of $3.30 and adjusted EPS of $3.69[3][4].

First-half cash flow improved on last year, and debt fell as a maturing note was repaid. Operating cash flow for the first half of 2026 was $1.842 billion, $481 million more than the $1.361 billion in the same period of 2025, which the company attributed to working-capital changes[31][32]. Stryker repaid $1.000 billion of maturing 3.500% senior unsecured notes in March[33], total debt fell to $14.942 billion at the end of June, cash, cash equivalents and marketable securities stood at $3.476 billion[32], and inventories rose from $5.310 billion at the end of 2025 to $5.521 billion[31].

Operating Model

Stryker's revenue has two engines: capital equipment built to order, and implants and disposables consumed with each procedure. Capital equipment, including beds, emergency equipment, surgical power and navigation systems, endoscopy systems and Mako robots, depends on hospital capital budgets, the order backlog and factory capacity, typically converts to revenue with a lag of one or more quarters, and ships most heavily in the fourth quarter[20]; implants and disposables, including knees, hips, trauma and extremities products, and stroke and peripheral thrombectomy devices, track current-quarter procedure volume, the share Mako helps win and the company's ability to supply[16]. Nearly all of the 10.3% organic growth in 2025 came from volume[22], and 2026 adds two special variables: the release of the post-cyberattack backlog, which pushes revenue up but is limited by capacity, and the Inari plant outage, which pushes U.S. Vascular revenue down directly[6][12].

Profit depends on gross margin, selling expense and segment mix together. In 2025 the gross margin was 64.0%, research and development ran at about 6.5% of sales, and selling, general and administrative expense, mostly the direct sales force and channels, ran at about 34.4%[23]; the company said segment mix should weigh on gross margin for the foreseeable future because the lower-margin MedSurg and Neurotechnology segment is growing faster than Orthopaedics[23]. In the second quarter of 2026 the MedSurg and Neurotechnology operating margin was 28.1% and the Orthopaedics margin was 34.0%[34], so a change in orthopaedic volume moves profit more than an equal change in MedSurg, while manufacturing and supply-chain costs, tariffs and production absorption feed into gross margin within one or two quarters[35].

Cash flow equals net earnings plus depreciation and amortization minus working-capital investment, and amortization of acquired intangibles is a large non-cash item. Intangible amortization was $732 million in 2025[23], and roughly $4.28 billion of free cash flow after capital expenditure was more or less used up by $4.960 billion of acquisitions and $1.284 billion of dividends, with new borrowing covering the gap[25]. In 2026 management said acquisitions remain the first priority but that it plans to resume share repurchases in the third quarter with $1 billion of board authorization available[36], so second-half operating cash flow will directly affect whether buybacks happen.

Industry and Competitive Position

Stryker ranks among the top few global suppliers in almost every market it serves, but its rivals are equally large diversified device makers. In its 2025 annual report the company said it is one of five leading global competitors in each of Instruments, Medical, Vascular and Neuro Cranial, against rivals including Medtronic, Johnson & Johnson MedTech, Zimmer Biomet, Baxter, Terumo and Penumbra, and one of seven in Endoscopy[15]; in joint replacement, trauma and extremities and orthopaedic robotics it is one of four leading competitors alongside Zimmer Biomet, Johnson & Johnson MedTech and Smith & Nephew[16]. Mako is the main differentiator in orthopaedics: the annual report says it is available in more than 45 countries and has performed over one million Mako Total Knee procedures[16], management said on the second-quarter call that Mako has performed more than 2.5 million procedures across 47 countries[36], and Zacks noted that Zimmer Biomet just received U.S. clearance for its next-generation ROSA Shoulder System while Intuitive Surgical is expanding da Vinci 5 placements, showing continued hospital interest in robotic-assisted surgery[37].

The industry's main constraint is cost control by payers and hospitals, which limits Stryker's pricing power. The company warns in its annual report that hospital cost containment in the United States and elsewhere, reimbursement changes, provider consolidation and measures such as China's volume-based procurement keep pushing device prices down[38], which is the backdrop to price contributing only 0.4 point of growth in 2025[22]. The annual report gives only Stryker's competitive ranking in each market and does not disclose specific market shares, and comparable financial data for competitors is not compared here, so Stryker's share shifts against rivals cannot yet be quantified.

Core Debates

Can Stryker turn the hospital-equipment orders delayed by the March cyberattack into third-quarter sales fast enough?

This question decides whether the full-year growth guidance holds. The March 11 cyberattack interrupted order processing, manufacturing and shipping[28][29], holding first-quarter organic growth to 2.4% and cutting adjusted EPS 8.5%[9]. The company still guides to 8.3% to 9.3% full-year organic growth[5], but the first half delivered only about 5.8%, and management said the second half needs roughly 11% to reach the midpoint, resting its confidence on the capital equipment backlog[6], so the third quarter is the first full quarter to test whether capacity can keep up with orders.

The evidence supports a recovery but also shows it will not be easy. On the supportive side, second-quarter organic growth returned to 9.0%[3], U.S. Medical sales rose 12.6% to $945 million and U.S. Endoscopy grew 10.2%[10]; as early as the first quarter, management described a steady hospital capital spending environment and an elevated capital order book[39], and Zacks reported that Mako posted its best-ever second quarter for installations in both the U.S. and international markets[37]. On the other side, in July the company cut the top of its full-year range from 9.5% to 9.3%, citing visibility into the production ramp[11], and the peripheral vascular supply problem is still dragging on growth[12].

An alternative reading is that the second-quarter rebound was mostly a one-time catch-up of first-quarter shipments. U.S. Medical sales for the first half totaled $1.692 billion, up only 3.1%, which suggests a large part of the second quarter's 12.6% was recovering the first-quarter shortfall[10]. If the third quarter returns to a normal pace of about 9%, the full year would land only at the bottom of the range, and the fourth quarter would have to carry most of the 11% second-half growth management described. The transmission chain runs from hospital capital budgets and orders, through the beds, emergency equipment, power tools, endoscopy systems and Mako units backlogged during the attack, to factory ramp-up and shipments, and finally into Medical, Instruments, Endoscopy and Ortho Tech revenue, company organic growth and delivery on the full-year guidance.

The third-quarter report needs to answer three questions: whether company organic growth is at least the second quarter's 9.0% and close to 10.5%, whether U.S. Medical sales keep growing at double digits, and whether the company keeps its 8.3% to 9.3% full-year range. If third-quarter organic growth falls below 9.0% and the company blames capacity, or if it lowers the bottom of its organic growth range, the view that the backlog will be delivered in the second half weakens.

When will Stryker's U.S. vascular sales stop falling after supply problems at the Inari plant it bought for $4.8 billion?

Peripheral vascular is where Stryker's largest recent acquisition landed, and the longer the outage lasts, the harder the cost is to recover. Inari was the company's largest acquisition of 2025, at $4.810 billion net[18], and it lifted Vascular sales 50.6% to $1.968 billion that year[14]. Most peripheral vascular products come from a single plant, process problems after the cyberattack created a meaningful back-order position, and second-quarter U.S. Vascular sales fell 6.7% to $250 million from $268 million a year earlier[10][12]; thrombectomy procedures are often emergencies that cannot be delayed, so hospitals switch to a competitor when stock runs out[11].

The company's account of the recovery is upbeat, but it has also acknowledged some lost share. On the July call management said the back orders were already being worked down and would reach manageable levels by the end of the third quarter, stressing that the problem was internal supply rather than market demand[11]; in the same quarter international Vascular still grew 4.0% in constant currency[10], and the AVS acquisition completed in May added a lithotripsy product to peripheral vascular[19]. Against that, the company admitted it lost some second-quarter sales because emergent procedures could not wait, and that by prioritizing core high-volume customers it limited new-customer growth[11]; on September 8, CFO Preston Wells said at the Wells Fargo Healthcare Conference that supply problems the company had hoped to resolve in the third quarter may continue into the fourth[40].

An alternative reading is that competitors entered hospitals during the outage, so even after supply recovers, U.S. Vascular could need several quarters to return to its growth rate at the time of the acquisition. The transmission chain here is short: capacity at the single Inari plant and its post-cyberattack process recovery determine how many peripheral thrombectomy devices can be supplied, which determines whether emergency procedures can use Stryker products; a stock-out means a lost case, which ultimately lowers U.S. Vascular revenue, MedSurg segment growth and company organic growth. The company does not separately disclose peripheral vascular revenue or the size of the back orders, so only the overall U.S. Vascular figure can be used as an indirect gauge.

The third-quarter report needs to show whether U.S. Vascular is better than the second quarter's -6.7%, whether the company confirms the back orders are at a manageable level, and whether international Vascular keeps growing. If the U.S. Vascular decline widens, or the company pushes recovery beyond the fourth quarter, the view that the outage is only a temporary shortage weakens and the likelihood of permanent customer loss rises.

Hip sales growth fell from nearly 9% last year to 2.6% in the second quarter. Is that temporary, or is joint-replacement demand weakening?

Knees and hips are among Stryker's most profit-sensitive businesses, so a demand shift is magnified in earnings. Knee and hip sales together totaled $4.521 billion in 2025, about 18% of company sales[16], and the Orthopaedics segment's second-quarter operating margin of 34.0% was above the 28.1% of MedSurg and Neurotechnology[34]. Hips grew 8.9% in constant currency in 2025[14], but only 2.6% in the second quarter of 2026, with international hips at -0.8%[41]; meanwhile, Medicare has proposed reimbursement cuts for large joint replacements, which would affect hospitals' tolerance for implant prices over a longer horizon[12].

The evidence partly supports a temporary slowdown but also contains clear counterexamples. On the supportive side, second-quarter knees grew 8.0% and Ortho Tech 10.0% in constant currency[41], and management said long-term joint-replacement demand is unchanged and that it anticipates a final Medicare outcome milder than the proposal[11]. On the other side, international hips are already declining[41], first-quarter Orthopaedics organic growth was only 4.1%[9], and summer is normally a slow season for orthopaedic implant surgery[20].

An alternative reading is that the hip slowdown comes mainly from demand rather than from the aftermath of the cyberattack. At the Wells Fargo conference in September, the CFO cited a softer year for joint replacement in Europe and U.S. patients deferring procedures because of inflation and higher deductibles[40], problems that will not fade on their own as cyberattack effects recede. The transmission chain runs from population aging, European public health budgets, U.S. patient out-of-pocket costs and Medicare reimbursement to knee and hip procedure volume at hospitals and ambulatory surgery centers, then through the share driven by Mako and new products into Knees and Hips sales, and finally into Orthopaedics revenue and its segment margin of about 34%.

The third-quarter report needs to show whether constant-currency hip growth exceeds 2.6%, whether knees hold above 6%, and whether Orthopaedics organic growth is at least the roughly 6.3% average of the first two quarters (4.1% in the first quarter and 8.6% in the second)[9][3]. If hip growth slips further and knees follow, or the final Medicare rule cuts joint-replacement payments sharply, the view that the slowdown is only seasonal and temporary weakens.

With cyberattack remediation costs still running, can Stryker deliver the more than 13% second-half earnings growth its guidance implies?

Whether the full-year EPS guidance holds depends on whether second-half margins can keep expanding while remediation costs remain. In the first quarter the cyberattack cut the adjusted operating margin 180 basis points and adjusted EPS 8.5%[9], and in the second quarter the margin expanded 170 basis points[3]. The company guides full-year adjusted EPS to $14.95 to $15.10[5]; first-half adjusted EPS totaled $6.29, above $5.97 in the same period of 2025[9][3][42], and measured against full-year 2025 adjusted EPS of $13.63, the second half needs growth of 13.1% to 15.0%[21]. The company said second-quarter tariff benefits were offset by idle-capacity and IT remediation costs that will continue into the second half[6].

The second-quarter margin improvement was solid, but part of it came from factors that will not last. On the supportive side, the second-quarter adjusted gross margin was 66.0%, up 60 basis points[36], the MedSurg and Neurotechnology segment margin rose 250 basis points to 28.1% and the Orthopaedics margin rose 90 basis points to 34.0%[34]; first-half operating cash flow was $1.842 billion, $481 million more than a year earlier[31], and the company plans to resume buybacks in the third quarter[36]. On the other side, manufacturing and supply-chain costs reduced the first-half gross margin by 100 basis points, mainly because of idle production time from the first-quarter cyberattack[35], management flagged rising raw material costs including oil[12], and in July the company did not add the second-quarter profit beat to its full-year guidance but used it to absorb cyberattack costs[11].

An alternative reading is that part of the second-quarter margin expansion came from one-off tailwinds such as lower tariffs. The reported second-quarter gross margin was 68.3%, of which 260 basis points came from reversing 2025 tariffs, a $158 million item excluded from adjusted results[35][43], but management also said the adjusted margin expansion itself included a net tariff benefit[36]. If tariff benefits fade in the third quarter while remediation spending does not, the margin would fall back to last year's level. The transmission chain runs from recovering output, which improves fixed-cost absorption, and lower tariffs, which lift gross margin, against IT remediation, idle capacity and higher raw material costs, which offset part of the gain; together they set the adjusted gross and operating margins and then adjusted EPS, while operating cash flow determines whether buybacks resume and therefore the share count.

The third-quarter report needs to show whether adjusted EPS grows 13% or more year over year, whether the adjusted operating margin keeps expanding, and whether the company resumes buybacks as planned. Notably, the third-quarter consensus EPS of $3.56 implies growth of about 11.6%[7][2], below the average pace the second half requires. If the third-quarter adjusted operating margin contracts year over year, or the company lowers its full-year adjusted EPS guidance, the view that growth can absorb remediation costs weakens.

Risks and Falsifiers

Tariffs, raw materials and geopolitical conflict could raise costs and slow international growth at the same time, and that risk falls directly on adjusted operating income. Adjusted operating income was $6.603 billion in 2025[24], and on the second-quarter call management said raw material costs including oil remain a headwind and the conflict in Iran is a modest drag on overall growth[12]. If the second-half gross margin stays above the 2025 reported level of 64.0%[23] and international organic growth is no lower than the second quarter's 8.9%[36], the risk has not materialized.

Acquisitions are Stryker's first priority, and an integration misstep could again interrupt supply and hit both revenue and debt. At the end of June total debt was $14.942 billion against $3.476 billion of cash and marketable securities[32], AVS carries up to $400 million in additional milestone payments[19], and the Inari plant problem has already shown that integration and supply risk flows straight into revenue[11]. If no new integration-related supply disruption appears in the second half and net debt falls with operating cash flow, the risk can be treated as contained.

A production ramp that lags orders is the most direct threat to the full-year revenue guidance: if backlogged capital equipment does not ship in the second half, the revenue slides into 2027. The 8.3% to 9.3% range needs roughly 11% organic growth in the second half[5][6], and on second-half 2025 sales of $13.228 billion, each percentage point of shortfall in second-half growth means about $130 million less revenue[8]. If third-quarter organic growth is at least 10.5% and the company keeps its full-year range, the risk recedes markedly.

If the peripheral vascular outage persists, a temporary shortage could turn into permanent share loss. Vascular is about 8% of company sales, second-quarter U.S. Vascular sales were about $18 million lower than a year earlier[10], a prolonged outage would keep weighing on organic growth[12], and it could put Inari-related goodwill and intangibles under impairment-testing pressure[18]. If third-quarter U.S. Vascular turns positive year over year and the company confirms the back orders are manageable, the risk is falsified.

Weaker joint-replacement demand combined with lower Medicare payments would be magnified in operating income through the high-margin Orthopaedics segment. Knee and hip sales totaled $4.521 billion in 2025[16] and the Orthopaedics segment margin is about 34%[34], so an equal revenue slowdown hurts operating income more than in MedSurg. If third-quarter hip growth returns above 5% and knees hold above 6%[41], the risk has not materialized.

If cyberattack remediation and idle-capacity costs persist, they will erode second-half profit. Manufacturing and supply-chain costs reduced the first-half gross margin by 100 basis points[35], and on second-half 2025 sales of $13.228 billion, every 50 basis points of lower second-half adjusted operating margin means about $66 million less operating income[8]. If the third-quarter adjusted operating margin expands year over year and the manufacturing cost drag narrows, the risk is falsified.

What to Watch Next

These are the indicators, current baselines and decision conditions for each core debate in the third-quarter report.

• Capital backlog conversion: organic growth was 9.0% in the second quarter and 2.4% in the first; U.S. Medical sales were $945 million, up 12.6%; full-year guidance is 8.3% to 9.3%. Organic growth of at least 10.5% with guidance intact would confirm the recovery; growth below 9.0% blamed on capacity, or a lower bottom of the range, would falsify it.
• Inari supply outage: U.S. Vascular sales were $250 million, down 6.7%, and the company said back orders would be manageable by the end of the third quarter. A positive year-over-year comparison with back orders confirmed manageable would confirm recovery; a wider decline or a recovery pushed beyond the fourth quarter would falsify it.
• Hip slowdown: hips grew 2.6% in constant currency with international at -0.8%, knees grew 8.0%, and Orthopaedics organic growth averaged about 6.3% over two quarters. Hips back above 5% would confirm a temporary slowdown; further hip deceleration with knees following, or a sharp final Medicare cut, would falsify it.
• Earnings under remediation costs: second-quarter adjusted EPS was $3.69, up 17.9%, the adjusted operating margin was 27.4%, up 170 basis points, and the second half needs 13.1% to 15.0% EPS growth. Year-over-year margin expansion would confirm; margin contraction or lower EPS guidance would falsify.

Conclusion

Stryker's business runs on two engines: capital equipment that hospitals buy from their budgets, and implants and disposables consumed with each procedure, and nearly all of 2025's $25.116 billion in sales and 10.3% organic growth came from volume[21][22]. The March 2026 cyberattack disrupted that machine, holding first-quarter organic growth to 2.4%[9]; the second quarter recovered to 9.0% organic growth and a 27.4% adjusted operating margin[3], but the full-year guidance requires roughly 11% second-half organic growth[6] and more than 13% growth in adjusted EPS. The central unresolved relationship is whether the pace of backlog shipments can outrun three drags: the peripheral vascular outage, the hip slowdown and remediation costs.

The two independent commentaries published after the second-quarter results overlap on some points and diverge on others. In an August 13 article for Zacks Investment Research, Indrajit Bandyopadhyay argued that the core question is capacity: the company has the orders to support high growth but must manufacture enough capital equipment to turn demand into sales, while cyber remediation spending, manufacturing and supply-chain pressure and the peripheral vascular shortage will limit operating leverage, and he treated whether the vascular back orders become manageable by the end of the third quarter as a risk to the recovery's cadence[37]. Elise Reuter of MedTech Dive reported on September 10 that the CFO told the Wells Fargo Healthcare Conference that peripheral vascular supply problems may continue into the fourth quarter and that summer hip sales were slower than expected, while capital equipment demand remained strong; the report cited William Blair analyst Steven Lichtman's view that the cyberattack disrupted the integration of the Inari plant into Stryker's systems with ripple effects, noted that the shares fell 9.7% from the day of the conference to the next day's open, and said the company did not change its guidance[40]. Both pieces agree that capital equipment demand is not the problem; they differ on the timing of the vascular recovery, with Zacks accepting the company's July statement that back orders would be manageable by the end of the third quarter, while the September report pushes that timing later and attributes the hip slowdown to demand pressure in Europe and among U.S. patients rather than to the cyberattack. These are outside interpretations, not facts, and they should not be read as a vote.

The current understanding would be materially strengthened by a combination of observations appearing together: third-quarter organic growth of at least 10.5%, double-digit growth in U.S. Medical, a narrower or positive U.S. Vascular comparison, hip growth back above 5%, continued year-over-year expansion in the adjusted operating margin, and a company that keeps its full-year guidance and resumes buybacks. Conversely, organic growth below 9.0% attributed to capacity, a wider U.S. Vascular decline, hips and knees slowing together, or a cut to either full-year guidance range would show that the post-cyberattack catch-up is slower than management described in July, leaving more of the second-half growth dependent on the fourth quarter or even 2027.

Sources

[1] SYK 10-K filed 2026-02-11 · business, products and segments · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[2] Drillr earnings calendar (updated 2026-10-01) · SYK 2026-10-29 call · 2026-10-01 · Drillr earnings calendar

[3] SYK 8-K filed 2026-07-30 · Q2 2026 results headline · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm

[4] SYK 8-K filed 2026-07-30 · Q2 2026 income statement · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm

[5] SYK 8-K filed 2026-07-30 · FY2026 guidance · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm

[6] SYK Q2 2026 earnings call 2026-07-30 · guidance and second-half cadence · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[7] Drillr analyst_financial_estimates (updated 2026-10-01) · SYK quarter ending 2026-09-30 · 2026-10-01 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[8] SYK 10-K filed 2026-02-11 · 2025 quarterly net sales · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[9] SYK 8-K filed 2026-04-30 · Q1 2026 results headline and guidance · 2026-04-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000025/sykex991earningsq12026.htm

[10] SYK 8-K filed 2026-07-30 · Q2 2026 MedSurg and Neurotechnology sales by business · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm

[11] SYK Q2 2026 earnings call 2026-07-30 · Q&A on guidance, Medicare and vascular supply · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[12] SYK Q2 2026 earnings call 2026-07-30 · stated risks · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[13] SYK 10-K filed 2026-02-11 · employees · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[14] SYK 10-K filed 2026-02-11 · 2025 net sales by segment and business · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[15] SYK 10-K filed 2026-02-11 · MedSurg and Neurotechnology businesses and competitors · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[16] SYK 10-K filed 2026-02-11 · Orthopaedics composition and Mako · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[17] SYK 8-K filed 2026-06-26 · recast 2025 financials under new organization · 2026-06-26 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000041/syk-20260626_d2.htm

[18] SYK 10-K filed 2026-02-11 · Inari acquisition · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[19] SYK 10-Q filed 2026-07-31 · AVS acquisition · 2026-07-31 · 10-Q · https://www.sec.gov/Archives/edgar/data/310764/000031076426000050/syk-20260630.htm

[20] SYK 10-K filed 2026-02-11 · raw materials, inventory and seasonality · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[21] SYK 10-K filed 2026-02-11 · overview of 2025 results · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[22] SYK 10-K filed 2026-02-11 · 2025 net sales drivers volume and price · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[23] SYK 10-K filed 2026-02-11 · gross profit and segment operating margin drivers · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[24] SYK 10-K filed 2026-02-11 · 2025 adjusted operating income reconciliation · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[25] SYK 10-K filed 2026-02-11 · 2025 cash flow, capex and dividends · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[26] SYK 10-K filed 2026-02-11 · liquidity and debt maturities · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[27] SYK 10-K filed 2026-02-11 · contractual obligations · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[28] SYK 8-K filed 2026-03-11 · cybersecurity incident · 2026-03-11 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000119312526102460/d76279d8k.htm

[29] SYK 8-K filed 2026-03-12 · operations disrupted · 2026-03-12 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000119312526104431/d101097d8k.htm

[30] SYK 8-K/A filed 2026-04-09 · material impact on first quarter · 2026-04-09 · 8-K/A · https://www.sec.gov/Archives/edgar/data/310764/000119312526149607/d112875d8ka.htm

[31] SYK 8-K filed 2026-07-30 · June 30 2026 balance sheet and H1 cash flow · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm

[32] SYK 10-Q filed 2026-07-31 · H1 2026 cash flow and liquidity · 2026-07-31 · 10-Q · https://www.sec.gov/Archives/edgar/data/310764/000031076426000050/syk-20260630.htm

[33] SYK 10-Q filed 2026-07-31 · debt and commercial paper · 2026-07-31 · 10-Q · https://www.sec.gov/Archives/edgar/data/310764/000031076426000050/syk-20260630.htm

[34] SYK 10-Q filed 2026-07-31 · segment operating margin drivers · 2026-07-31 · 10-Q · https://www.sec.gov/Archives/edgar/data/310764/000031076426000050/syk-20260630.htm

[35] SYK 10-Q filed 2026-07-31 · gross margin bridge and cyber idle production · 2026-07-31 · 10-Q · https://www.sec.gov/Archives/edgar/data/310764/000031076426000050/syk-20260630.htm

[36] SYK Q2 2026 earnings call 2026-07-30 · management highlights and capital deployment · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[37] Zacks Investment Research 2026-08-13 · Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half? · 2026-08-13 · Zacks Investment Research · https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html

[38] SYK 10-K filed 2026-02-11 · pricing pressure and reimbursement risk · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm

[39] SYK Q1 2026 earnings call 2026-04-30 · cyber impact, demand and order book · 2026-04-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[40] MedTech Dive 2026-09-10 · Stryker stock falls on slower peripheral vascular, hip sales · 2026-09-10 · MedTech Dive · https://www.medtechdive.com/news/stryker-stock-falls-on-slower-peripheral-vascular-hip-sales/830060/

[41] SYK 8-K filed 2026-07-30 · Q2 2026 Orthopaedics sales by business · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm

[42] SYK 8-K filed 2026-07-30 · Q2 2025 non-GAAP reconciliation · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm

[43] SYK 8-K filed 2026-07-30 · Q2 2026 non-GAAP reconciliation · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm